LONDON (SHARECAST) - Pharmaceuticals group Shire raced ahead of bigger rivals GlaxoSmithKline and AstraZeneca with its third quarter sales, posting growth of 24% from the same period the previous year.
Total revenues came in at �1.086bn for the three months to 30 September, while operating income came in at $341m. Earlier in the week Glaxo posted growth of 4% in third quarter sales, while Astra�s were down by 2%.
Shire, which was boosted by strong sales of the hyperactivity treatment Vyvanse and Replagal, a treatment for Fabry�s disease, a rare condition that causes full-body pain, said it remains on track to deliver full year results in line with expectations.
�Shire has delivered another strong set of quarterly results,� said chief executive Angus Russell.
�Total product sales were up 28% to $1,018m, with our newly acquired regenerative medicine product, DERMAGRAFT for Diabetic Foot Ulcers, contributing sales of $50 million in the quarter.�
At 1.15pm, shares in Shire were down by 24p at 1,949p.
Total revenues came in at �1.086bn for the three months to 30 September, while operating income came in at $341m. Earlier in the week Glaxo posted growth of 4% in third quarter sales, while Astra�s were down by 2%.
Shire, which was boosted by strong sales of the hyperactivity treatment Vyvanse and Replagal, a treatment for Fabry�s disease, a rare condition that causes full-body pain, said it remains on track to deliver full year results in line with expectations.
�Shire has delivered another strong set of quarterly results,� said chief executive Angus Russell.
�Total product sales were up 28% to $1,018m, with our newly acquired regenerative medicine product, DERMAGRAFT for Diabetic Foot Ulcers, contributing sales of $50 million in the quarter.�
At 1.15pm, shares in Shire were down by 24p at 1,949p.
ليست هناك تعليقات:
إرسال تعليق